Exane Derivatives’s Sage Therapeutics SAGE Stock Holding History

Exane Derivatives’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$452	Hold	14	–	–	﹤0.01%	582
2022 Q1	$463	Hold	14	–	–	﹤0.01%	870
2021 Q4	$596	Hold	14	–	–	﹤0.01%	753
2021 Q3	$620	Sell	14 -376	-96%	-$17.2K	﹤0.01%	919
2021 Q2	$20.5K	Hold	390	–	–	﹤0.01%	700
2021 Q1	$29.2K	Hold	390	–	–	0.01%	550
2020 Q4	$33.7K	Buy	390 +384	+6,400%	+$28.3K	0.01%	489
2020 Q3	$367	Hold	6	–	–	﹤0.01%	698
2020 Q2	$249	Hold	6	–	–	﹤0.01%	649
2020 Q1	$172	Hold	6	–	–	﹤0.01%	663
2019 Q4	$449	Hold	6	–	–	﹤0.01%	621
2019 Q3	$842	Hold	6	–	–	﹤0.01%	548
2019 Q2	$1.1K	Hold	6	–	–	﹤0.01%	553
2019 Q1	$954	Hold	6	–	–	﹤0.01%	502
2018 Q4	$575	Hold	6	–	–	﹤0.01%	600
2018 Q3	$834	Sell	6 -656	-99%	-$101K	﹤0.01%	553
2018 Q2	$103K	Hold	662	–	–	0.02%	331
2018 Q1	$103K	Buy	+662	New	+$112K	0.02%	298

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Exane Derivatives's SAGE Position: Q2 2022 in Review

Exane Derivatives held its Sage Therapeutics (SAGE) position steady in Q2 2022 at 14 shares worth $452. The position accounts for ﹤0.01% of the portfolio, ranked #582.

Exane Derivatives first reported a position in SAGE in Q1 2018 and has held it in 18 quarters since. The position peaked at $103K in Q1 2018. 210 funds tracked by Wall St. Rank hold SAGE as of Q2 2022.

Exane Derivatives held 14 shares of Sage Therapeutics worth $452 as of Q2 2022.
Exane Derivatives left its Sage Therapeutics share count unchanged in Q2 2022.
Sage Therapeutics made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #582 holding.
Exane Derivatives first reported a position in Sage Therapeutics in Q1 2018 and has held it in 18 quarters since.
Exane Derivatives's Sage Therapeutics position peaked at $103K in Q1 2018.
210 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.